The coxibs, selective inhibitors of cyclooxygenase-2.
暂无分享,去创建一个
[1] B. Thjódleifsson,et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen , 2001, Gut.
[2] P. Schoenfeld. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. , 1999, The American journal of medicine.
[3] E. Remmers,et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. , 1994, The Journal of clinical investigation.
[4] R. Lorenz,et al. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen , 1999, Nature Medicine.
[5] A. Martens,et al. Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis , 1999, Annals of the rheumatic diseases.
[6] R. Erikson,et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[7] D. Dixon,et al. Transforming Growth Factor-β1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA* , 2000, The Journal of Biological Chemistry.
[8] J. Johnston,et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II , 1995, Nature.
[9] D. Graham,et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.
[10] K. Goa,et al. Celecoxib , 2000, Drugs.
[11] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[12] V. Winn,et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] L. Spain,et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. , 1999, The Journal of clinical investigation.
[14] M. Malkowski,et al. The productive conformation of arachidonic acid bound to prostaglandin synthase. , 2000, Science.
[15] B. Connolly,et al. Immunolocalization of cyclooxygenase‐2 in the macula densa of human elderly , 1999, FEBS letters.
[16] M. Feldman,et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.
[17] B. Gertz,et al. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers , 2000, Journal of clinical pharmacology.
[18] P. Isakson,et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.
[19] G. FitzGerald,et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. , 2000, The Journal of clinical investigation.
[20] D. Fitzgerald,et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. , 1998, The Journal of pharmacology and experimental therapeutics.
[21] C. Patrono,et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. , 1999, The Journal of pharmacology and experimental therapeutics.
[22] S. Prescott. Is cyclooxygenase-2 the alpha and the omega in cancer? , 2000, The Journal of clinical investigation.
[23] A. Singh,et al. Review Nimesulide: Some Pharmaceutical and Pharmacological Aspects—An Update , 2000 .
[24] C. Patrono,et al. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. , 2000, Epidemiology.
[25] P. Libby,et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.
[26] S. R. Dahlqvist,et al. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. , 2000, The Journal of rheumatology.
[27] J. Bolognese,et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. , 2000, Archives of internal medicine.
[28] Daniel Picot,et al. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.
[29] N. Davies,et al. Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib , 2000, Clinical pharmacokinetics.
[30] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] Sharon R. Adderley,et al. Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2* , 1999, The Journal of Biological Chemistry.
[32] C. Patrono,et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[33] R. Bolli,et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.
[35] A. Whelton,et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. , 2000, American journal of therapeutics.
[36] M. Kasuga,et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. , 1997, Gastroenterology.
[37] C. Patrono,et al. The clinical significance of inhibition of renal prostaglandin synthesis. , 1987, Kidney international.
[38] C. Hawkey,et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. , 1998, British journal of rheumatology.
[39] J. Wallace,et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. , 1996, The Journal of clinical investigation.
[40] V. Fuster,et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.
[41] H Perrier,et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.
[42] A. Schmaier,et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. , 2000, Arthritis and rheumatism.
[43] R. Sartor,et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. , 2000, The Journal of clinical investigation.
[44] R. S. Rogers,et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.
[45] C. Patrono,et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings , 1998, Clinical pharmacology and therapeutics.
[46] H R Herschman,et al. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. , 1992, The Journal of biological chemistry.
[47] J. Oates,et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[48] K. Schrör,et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. , 1998, Molecular pharmacology.
[49] M. Feldman,et al. Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity? , 2000, Annals of Internal Medicine.
[50] K. Seibert,et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] R. Hubbard,et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. , 1999, The Journal of rheumatology.
[52] A. D. Rodrigues,et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. , 2000, The Journal of pharmacology and experimental therapeutics.
[53] R Gordon,et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.
[54] S. Hart,et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. , 1992, The Journal of biological chemistry.
[55] A. Macciocchi,et al. Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. , 1994, European journal of rheumatology and inflammation.
[56] J. Bolognese,et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. , 2000, Arthritis and rheumatism.
[57] C. Patrono,et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.
[58] S. Swan,et al. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet , 2000, Annals of Internal Medicine.
[59] J. M. Bailey,et al. Inhibition by corticosteroids of epidermal growth factor‐induced recovery of cyclooxygenase after aspirin inactivation , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] A. van Hecken,et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans , 2000, European Journal of Clinical Pharmacology.
[61] J. Lötsch,et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state , 1999, Clinical pharmacology and therapeutics.
[62] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[63] L. G. García Rodríguez,et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. , 1998, Archives of internal medicine.
[64] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[65] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Morrow,et al. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA. , 1997, Advances in experimental medicine and biology.
[67] M. Hori,et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.
[68] S. R. Dahlqvist,et al. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. , 1997, The Journal of rheumatology.
[69] D. Gilroy,et al. Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.
[70] L. Crofford,et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. , 1999 .
[71] J. Bolognese,et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.
[72] L. Marnett,et al. Arachidonic Acid Oxygenation by COX-1 and COX-2 , 1999, The Journal of Biological Chemistry.
[73] P. Lipsky,et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.
[74] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[75] J. Oates,et al. Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.
[76] A. K. Pedersen,et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.
[77] M. Gimbrone,et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[78] R. Bible,et al. Metabolism and Excretion of [14C]Celecoxib in Healthy Male Volunteers , 2000 .
[79] J. Senior,et al. Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs , 1995, Annals of Internal Medicine.
[80] D. Riendeau,et al. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). , 2000, Bioorganic & medicinal chemistry letters.
[81] K. Seibert,et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. , 1990, The Journal of clinical investigation.
[82] C. Hawkey,et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. , 2000, Arthritis and rheumatism.
[83] G. FitzGerald,et al. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. , 1991 .
[84] M. Breyer,et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. , 2000, Kidney international.
[85] C. Hawkey,et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. , 1998, British journal of rheumatology.
[86] A. Whelton,et al. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.
[87] S. Hernández-Díaz,et al. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents , 2000, Arthritis Research & Therapy.
[88] A. Macciocchi,et al. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. , 1994, European journal of rheumatology and inflammation.
[89] S. Iacobelli,et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.
[90] G. FitzGerald,et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.